With almost a dozen vaccine candidates in clinical trials, tuberculosis (TB) research and
development is finally reaping the first fruits of its labors. Vaccine candidates in clinical trials …

Mycobacterium tuberculosis, the causative agent of tuberculosis, has infected humans for
millennia. M. tuberculosis is well adapted to establish infection, persist in the face of the host …

The different manifestations of infection with Mycobacterium tuberculosis reflect the balance
between the bacillus and host defense mechanisms. Traditionally, protective immunity to …

Tuberculosis (TB) poses a great challenge to immunologists, as it represents a chronic
infection characterized by persistence of the pathogen despite development of antigen …

A major challenge in tuberculosis (TB) is to improve current vaccination and therapeutic
strategies and this requires a fine understanding of the mechanisms that mediate protection …

Breakthrough findings in the clinical and preclinical development of tuberculosis (TB)
vaccines have galvanized the field and suggest, for the first time since the development of …

Tuberculosis is primarily a disease of the lung, and dissemination of the disease depends
on productive infection of this critical organ. Upon aerosol infection with Mycobacterium …

Tuberculosis (TB) is the leading killer among all infectious diseases worldwide despite
extensive use of the Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine. A safer …

Tuberculosis (TB) is a highly contagious infection and devastating chronic disease, causing
10.4 million new infections and 1.8 million deaths every year globally. Efforts to control and …

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) infection, remains a major
global health emergency. It is estimated that one third of global population are affected …